CLSD
(NASDAQ)
1.58
+0.0678  (+4.29%)
Volume (24h): 156.32K Day Range: 1.47 - 1.68
Market Cap: 70.89M 52W Range: 0.5640 - 4.13
Mar-31-20 12:15AM Edited Transcript of CLSD earnings conference call or presentation 11-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Mar-30-20 06:44AM Edited Transcript of CLSD earnings conference call or presentation 11-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Mar-27-20 05:50PM Edited Transcript of CLSD earnings conference call or presentation 11-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Mar-12-20 07:00AM Edited Transcript of CLSD earnings conference call or presentation 11-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Mar-11-20 09:45PM Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue EstimatesZacks
08:05PM Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
Mar-11-20 08:04PM Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive OfficerGlobeNewswire
08:03PM Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South KoreaGlobeNewswire
Mar-11-20 06:30PM Clearside Biomedical, Inc. to Host Earnings CallACCESSWIRE
Mar-04-20 05:30PM Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks
Feb-27-20 12:05PM Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020GlobeNewswire
Feb-26-20 12:05PM Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020GlobeNewswire
Feb-25-20 12:05PM Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society MeetingsGlobeNewswire
Feb-05-20 12:05PM Clearside Biomedical Announces Presentations to be Given at Angiogenesis and Macula Society ConferencesGlobeNewswire
Jan-28-20 12:36PM Bausch Health, Clearside Biomedical publish data on eye drugMarketWatch
12:00PM Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in OphthalmologyPR Newswire
Jan-20-20 11:28AM Will Clearside Biomedical Continue to Surge Higher?Zacks
Jan-06-20 12:05PM Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
Dec-31-19 12:09PM Calculating The Intrinsic Value Of Clearside Biomedical, Inc. (NASDAQ:CLSD)Simply Wall St.
Dec-24-19 05:15PM Biotech Leading in Q4: Best ETFs & StocksZacks
Dec-18-19 02:10PM Is the Options Market Predicting a Spike in Clearside Biomedical (CLSD) Stock?Zacks
Nov-29-19 03:29PM These 3 Biotech Stocks Could More Than Double in 2020, Says WedbushTipRanks
Nov-22-19 10:19PM Edited Transcript of CLSD earnings conference call or presentation 6-Nov-19 9:30pm GMTThomson Reuters StreetEvents
04:35PM Edited Transcript of CLSD earnings conference call or presentation 6-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Nov-13-19 09:05PM Clearside Biomedical to Present at the Stifel 2019 Healthcare ConferenceGlobeNewswire
Nov-07-19 12:05AM Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue EstimatesZacks
Nov-06-19 09:05PM Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
Oct-30-19 08:05PM Clearside Biomedical to Report Third Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, November 6, 2019GlobeNewswire
11:05AM Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy DeliveryGlobeNewswire
Oct-23-19 11:54AM The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer DataBenzinga
10:55AM Bausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With UveitisCNW Group
Oct-17-19 08:05PM Clearside Biomedical Suprachoroidal Injection Platform Featured in Multiple Presentations at the American Academy of Ophthalmology (AAO) 2019 Annual MeetingGlobeNewswire
Oct-13-19 08:33PM The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma EarningsBenzinga
Oct-03-19 11:05AM Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual MeetingGlobeNewswire
Sep-19-19 11:05AM Clearside Biomedical Featured at Multiple European Scientific Retinal CongressesGlobeNewswire
Sep-17-19 10:27AM Those Who Purchased Clearside Biomedical (NASDAQ:CLSD) Shares Three Years Ago Have A 93% Loss To Show For ItSimply Wall St.
Sep-10-19 01:38AM Edited Transcript of CLSD earnings conference call or presentation 7-Aug-19 8:30pm GMTThomson Reuters StreetEvents
Sep-04-19 11:00AM REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314PR Newswire
Sep-03-19 08:05PM Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare ConferenceGlobeNewswire
Aug-28-19 02:34PM Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & MoreZacks
Aug-22-19 11:05AM Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)GlobeNewswire
Aug-08-19 12:25AM Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue EstimatesZacks
Aug-07-19 08:05PM Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)